IngenioRx will not be like the traditional PBMs, Anthem CEO Gail Boudreaux said in a presentation at the company’s investor day.
The in-house PBM will pass along rebates to customers at the pharmacy counter and work to simplify services for patients and employers.
“We are not building a rebate-focused PBM,” Ms. Boudreaux said during the presentation, according to Bloomberg. “We have the benefit and the advantage of building a next-generation PBM.”
PBMs have increasingly faced criticism from patients and lawmakers for helping drive prescription drug costs higher in the U.S. Critics of PBMs say the rebate system, in which drugmakers pay discounts to PBMs, helps keep list prices high, which harms patients who do not have insurance.
Read the full report here.
More articles on payers:
5 must-reads on payer-provider relationships
8 recent lawsuits involving payers
State of the payer market: the growing need for infrastructure and operations